I
Ian O. Ellis
Researcher at University of Nottingham
Publications - 1071
Citations - 84964
Ian O. Ellis is an academic researcher from University of Nottingham. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 126, co-authored 1051 publications receiving 75435 citations. Previous affiliations of Ian O. Ellis include Mansoura University & Curie Institute.
Papers
More filters
Journal ArticleDOI
Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.
Fresia Pareja,Michael S. Toss,Felipe C Geyer,Edaise M da Silva,Mahsa Vahdatinia,Ana Paula Martins Sebastiao,Pier Selenica,Austin Szatrowski,Marcia Edelweiss,Hannah Y Wen,Raluca Mihai,Zsuzsanna Varga,Maria Pia Foschini,Brian P. Rubin,Ian O. Ellis,Sarat Chandarlapaty,Achim A. Jungbluth,Edi Brogi,Britta Weigelt,Jorge S. Reis-Filho,Emad A. Rakha +20 more
TL;DR: The sensitivity and specificity of RAS Q 61R immunohistochemical (IHC) analysis for detection of HRAS Q61R mutations in AMEs was determined.
Journal ArticleDOI
A novel prognostic two-gene signature for triple negative breast cancer.
Mansour Alsaleem,Mansour Alsaleem,Graham Ball,Michael S. Toss,Sara Raafat,Mohammed A. Aleskandarany,Chitra Joseph,Angela Ogden,Shristi Bhattarai,Padmashree C.G. Rida,Francesca Khani,Melissa Davis,Olivier Elemento,Ritu Aneja,Ian O. Ellis,Andrew R. Green,Nigel P. Mongan,Nigel P. Mongan,Emad A. Rakha,Emad A. Rakha +19 more
TL;DR: This study identifies a prognostic gene signature that can predict prognosis in T NBC patients and could potentially be used to guide the clinical management of TNBC patients.
Journal ArticleDOI
Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.
Michael S. Toss,Michael S. Toss,Islam M. Miligy,Islam M. Miligy,Kylie L. Gorringe,Kylie L. Gorringe,Mohammed A. Aleskandarany,Mohammed A. Aleskandarany,Abdulbaqi AlKawaz,Karuna Mittal,Ritu Aneja,Ian O. Ellis,Andrew R. Green,Emad A. Rakha,Emad A. Rakha +14 more
TL;DR: Overexpression of stromal COL11A1 is associated with invasive recurrence in DCIS and is a potential marker to predict the response to radiotherapy, when incorporated with other risk factors and provided better patient risk stratification.
Journal ArticleDOI
Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer
Jillian Davis,Stewart G. Martin,Poulam M. Patel,Andrew R. Green,Emad A. Rakha,Ian O. Ellis,Sarah J. Storr +6 more
TL;DR: This study suggests that calpain-9 may play a role in breast cancer and that low expression is associated with poorer patient clinical outcome following endocrine therapy.